The estimated Net Worth of Elizabeth Scott Bolgiano is at least $1.87 Million dollars as of 9 May 2019. Elizabeth Bolgiano owns over 5,000 units of AMAG Pharmaceuticals stock worth over $1,871,175 and over the last 7 years Elizabeth sold AMAG stock worth over $0.
Elizabeth has made over 1 trades of the AMAG Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently Elizabeth bought 5,000 units of AMAG stock worth $54,650 on 9 May 2019.
The largest trade Elizabeth's ever made was buying 5,000 units of AMAG Pharmaceuticals stock on 9 May 2019 worth over $54,650. On average, Elizabeth trades about 1,000 units every 0 days since 2018. As of 9 May 2019 Elizabeth still owns at least 74,847 units of AMAG Pharmaceuticals stock.
You can see the complete history of Elizabeth Bolgiano stock trades at the bottom of the page.
Elizabeth's mailing address filed with the SEC is C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM, MA, 02451.
Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C...., and Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
AMAG Pharmaceuticals executives and other stock owners filed with the SEC include: